Orion lifts 2026 outlook as third-quarter sales climb 28%
Finnish pharma group Orion reported 28% sales growth and raised its 2026 forecast, driven by Nubeqa sales and royalty income.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Finnish pharmaceutical company Orion Oyj reported that third-quarter net sales rose 28% year on year, while basic earnings per share grew 74%. According to Reuters, growth came mainly from the Innovative Medicines and Branded Products divisions, and better profitability was largely due to higher royalty income.
The company raised its 2026 outlook, now expecting net sales of EUR 2,070 million to EUR 2,140 million and operating profit of EUR 730 million to EUR 790 million. Strong growth in Nubeqa royalties was the main reason for the upgrade.
why it matters
For investors, the key point is the guidance increase rather than the quarterly figures alone, signalling that the company's leading product is still expanding. According to LSEG data, the average analyst rating on the shares is hold, and the median 12-month price target is EUR 87.00, versus a EUR 95.75 close on October 27.
market impact
Orion shares: higher guidance and Nubeqa growth support the stock
- Orion Oyj shares pressure up — raised guidance and strong Nubeqa growth support demand for the stock
tags
instruments
sources
- Finland's Orion Q3 sales rise 28%; upgrades 2026 outlook — Reuters, 28 October 2026 at 10:09 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗